CHLA Clinical Research Studies

Having volunteers participate in research studies and clinical trials is critical to our research efforts. Thousands of children and families are involved in our patient-centered studies every year. Many of the treatments used today are based on the results of past research studies and clinical trials conducted with our patients. Our scientific and clinical experts take the best ideas from the laboratory -- to the patient -- in the form of promising new treatments.

By searching our study directory, you may identify research that could impact the life of your child or of another child you know. Because the number of available research studies and clinical trials for children nationwide is small, every participant makes a significant contribution.

In addition to enrolling children with certain diseases in order to study treatments and prevention of those diseases, we also need to study healthy children. Ask your child’s doctor about volunteer study options that may be suitable for your child.

Please contact the study staff listed in your search results for more information.

Search by Keyword:    

Back to the full listing

Study Details - ID: CCI-CG-06-00012
Health/Science/Disease Category:
Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL)
Short Name:
TACL / Amgen Carfilzomib study
Full Title of Study:
20140106 (formerly CFZ008); Phase 1b Study of Carfilzomib in Combination with Induction Chemotherapy in Children with Relapsed or Refractory Acute Lymphoblastic Leukemia
Phase/Type of Study:
Phase I drug treatment
Purpose of Research:
Carfilzomib (also known as Kyprolis®) is approved to be used in certain adult patients with relapsed or refractory multiple myeloma (myeloma that returns after a successful course of treatment or myeloma that does not respond to treatment). Multiple myeloma is a type of blood cancer. Carfilzomib is not approved to treat ALL. It has not been given in combination with the other drugs used in this study. This study is being done to find out if carfilzomib can be safely given before and during treatment with standard chemotherapy drugs.
Eligibility:
Age 1 to 21 with leukemia (ALL) that has returned after an initial response to treatment or failed to respond to initial treatment
Time Commitment/Requirements:
Subjects will receive a 4 week cycle of induction chemotherapy and have the option to receive a 4 week cycle of consolidation chemotherapy , if stable disease or better response is achieved at the end of the Induction Cycle.
Primary Investigator:
Paul S. Gaynon, MD
Coordinator Contact Name:
Ellynore Florendo, CCRC or Meg Fender, CRC -III
Phone Number:
323-361-5429
Email:
TACL@chla.usc.edu
Clinical Trials .Gov Identifier:
NCT02303821